| Ian Robert Symons, MBCHB | |
|
Cheshire Medical Centre Dhk, 580 Court Street, Keene, NH 03431 | |
| (603) 354-5454 | |
| Not Available |
| Full Name | Ian Robert Symons |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | Cheshire Medical Centre Dhk, Keene, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073861324 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheshire Medical Center | Keene, NH | Hospital |
| Brattleboro Memorial Hospital | Brattleboro, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Brattleboro Memorial Hospital | 9335112929 | 74 |
News Archive
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them.
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
› Verified 9 days ago
| Entity Name | Monadnock Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881676104 PECOS PAC ID: 7416933031 Enrollment ID: O20040625000075 |
News Archive
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them.
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them.
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
› Verified 9 days ago
| Entity Name | Cheshire Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093803397 PECOS PAC ID: 1456260165 Enrollment ID: O20070913000090 |
News Archive
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them.
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ian Robert Symons, MBCHB Cheshire Medical Centre Dartmouth Hitchcock Keene, 580-90 Court Street, Keene, NH 03431 Ph: (603) 354-5454 | Ian Robert Symons, MBCHB Cheshire Medical Centre Dhk, 580 Court Street, Keene, NH 03431 Ph: (603) 354-5454 |
News Archive
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the project with just over DKK 13 million.
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them.
WHO has been made aware of multiple, recent reports of eye injury, including blindness, with the use of chlorhexidine gluconate 7.1%, in nine countries in sub Saharan Africa.
› Verified 9 days ago
Dr. John A. Curtis Jr., MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 580 Court St, Emergency Department, Keene, NH 03431 Phone: 603-354-6600 Fax: 603-354-6605 | |
Dr. James Connolly Suozzi, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 580 Court Street, Keene, NH 03431 Phone: 603-354-6600 | |
Sarah Markus, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Emergency Medicine, Keene, NH 03431 Phone: 603-354-5400 | |
Dr. Thomas Cochran, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-5400 | |
Dr. Robert Khalil Hilo, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-5454 Fax: 603-354-6535 | |
Thomas A. Hennigan, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 580 Court Street The Cheshire Medical Center, Emergency Medicine Department, Keene, NH 03431 Phone: 603-354-6600 Fax: 603-354-6605 |